



PHONE NUMBER:
703-299-9766

WEB ADDRESS:
aasld.org

OFFICE ADDRESS:
1001 N. Fairfax Street, 4TH Floor,
Alexandria, VA 22314

EARLY DETECTION STARTS HERE

Free, Expert-Developed Education

 |  |  | 



**UNMASKING
MASH AND MASLD**

Bringing Metabolic Liver Disease to the Surface



ACCREDITATION AND DESIGNATION STATEMENT

CONTINUING MEDICAL EDUCATION (CME)

Accreditation Statement

The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The American Association for the Study of Liver Diseases (AASLD) designates this live activity for a maximum of 17.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming CME Credits

Physicians seeking AMA PRA Category 1 Credits™ for this live activity must complete the course evaluation by May 30, 2026. A link to the CME evaluation will be emailed to attendees after the course.

UNIFIED FRONTIERS IN LIVER DISEASE – TREATING STEATOSIS, CHOLESTASIS, AND BEYOND

**MARCH 13 – 15, 2026
LAS VEGAS, NEVADA**

CONFERENCE ORGANIZERS

On behalf of CALD Special Interest Group (SIG):

Craig Lammert, MD, MS
Cynthia Levy, MD, FAASLD
David Assis, MD
Cara Mack, MD, FAASLD

On behalf of MASLD Special Interest Group (SIG):

Alina Allen, MD
Mazen Nouredin, MD, MHS

PROGRAM AGENDA

FRIDAY, MARCH 13

Evolving Insights into Cholestatic Liver Disease Therapies and Methods to Disentangle Etiopathogenesis

Session 1: A New Therapeutic Era in Cholestatic Liver Disease Could Improve the Patient Experience and Outcomes (Part 1) –

Moderators: Cynthia Levy & Alan Bonder

- 8 am Immunological Landscape of PBC: Where Are We Coming from and Where Are We Going? | *Vincenzo Ronca*
- 8:20 am Current Treatment Landscape of Primary Biliary Cholangitis (PBC) | *Aparna Goel*
- 8:40 am Are We Ready for a Personalized Approach to PBC? | *Cynthia Levy*
- 9 am Disentangling the Overlap Syndromes (PBC and PSC + AIH/MASLD): From Diagnosis to New Treatments | *Marilyn Mayo*
- 9:20 am Panel Discussion / Q&A
- 9:40 am **BREAK & TABLETOP EXPO**

Session 2: A New Therapeutic Era in Cholestatic Liver Disease Could Improve the Patient Experience and Outcomes (Part 2) –

Moderators: David Assis & Sonya MacParland

- 10 am Immunobiologic Landscape of PSC: A Continuum of Time and Space | *Martin Cornillet*
- 10:20 am Emerging Therapies and Mechanisms in PSC | *David Assis*
- 10:40 am Deep Learning in PBC and PSC: Diagnosis and Prediction of Outcomes | *John Eaton*
- 11 am Oral Abstract Presentations: Clinical Connections in PSC/PBC – Primary Biliary Cholangitis with Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease Demonstrates Comparable Biochemical Response to Ursodeoxycholic Acid: Results from the ELLA-PBC Cohort | *Paul Yoon (tentative)*
- Possible/Unlikely Drug Induced Liver Injury Cases with Autoimmune Features are Significantly Enriched with Traditional AIH HLA Risk Alleles | *Craig Lammert*
- 11:20 am Panel Discussion / Q&A
- 11:40 pm **BREAK & TABLETOP EXPO**
- 12:15 pm **LUNCH WITH INDUSTRY SYMPOSIUM**
SPONSORED BY IPSEN BIOPHARMACEUTICALS
Evolving Approach to Second-Line Treatment in PBC | *Dr. Justin Reynolds*

Session 3: Methodologic Innovation Provides New Clues to Cholestatic Liver Disease Pathogenesis and Treatments (Part 1) –

Moderators: Pietro Invernizzi & Marilyn Mayo

- 1:15 pm Navigating the Drug Development Challenges of PBC in the Post-Marketing World | *Alan Bonder*
- 1:35 pm Lessons from Epigenetic (EWAS) Changes in PSC and PBC | *Pietro Invernizzi*
- 1:55 pm New Concepts on Pathophysiology and Treatment of Pruritus and Fatigue in Cholestatic Liver Diseases | *Mark Swain*
- 2:15 pm Genetic Underpinnings to Cholestatic Liver Disease | *Silvia Vilarinho*
- 2:35 pm Panel Discussion / Q&A
- 2:55 pm **BREAK & TABLETOP EXPO**

Session 4: Methodologic Innovation Provides New Clues to Cholestatic Liver Disease Pathogenesis and Treatments (Part 2) –

Moderators: Michael Trauner & Craig Lammert

- 3:15 pm Single Cell Sequencing and Immunologic Insights in Cholestasis | *Sonya MacParland*

- 3:35 pm Bile Acid Signaling in Cholestasis and Therapeutic Implications | *Michael Trauner*
- 3:55 pm Extrahepatic Cholangiocyte Organoids (Microphysiologic Systems) for Cholestatic Disease Modeling | *Ana Garcia Moreno*
- 4:15 pm Oral Abstract Presentations: Translational Connections in PSC/PBC – Hepatocyte TEAD1 selectively drives inflammatory and fibrogenic remodeling during DDC-induced cholestatic liver injury | *Amit Kumar (tentative)*
- Functional Differences of the Gut Microbiome in Primary Sclerosing Cholangitis and Primary Biliary Cholangitis Inform Pathogenesis and Therapeutic Interventions | *Marios Nikoladidis (tentative)*
- 5 pm Welcome Reception and Poster Presentation Showcase – Open to All Registered Attendees, food and drink provided
- 6:30 pm **DAY 1 ADJOURNED**

SATURDAY, MARCH 14

Steatotic Liver Disease: From Bench to Clinical Care and Public Policy

Session 1: The Science of SLD and Dysmetabolism –

Moderators: Mary Rinella and Rotonya Carr

- 8 am The Role of Metabolic Dysfunction and Alcohol in Steatohepatitis | *Rotonya Carr*
- 8:20 am Understanding the Role of Hunger/Satiety and Addiction Centers in SLD | *Samuel Klein*
- 8:40 am How Did Our Food and Environment Become Obesogenic in the Last Few Decades? | *Ani Kardashian*
- 9 am Antenatal MASH and Obesity – The Role of Maternal Health for the Next Generation | *Monika Sarkar*
- 9:20 am Panel Discussion / Q&A
- 9:40 am **BREAK & TABLETOP EXPO**

Session 2: Updates in MetALD –

Moderators: Mary Rinella and Mazen Noureddin

- 10 am How Should We Refine MetALD: Updates in Diagnosis and Biomarkers of Alcohol Use | *Brian Lee*
- 10:20 am Clinical Course of MetALD in the SLD Continuum | *Jessica Mellinger*
- 10:40 am Treatment Approaches in the Clinic: Examples of Effective Multidisciplinary Care That Include AUD Treatment | *Gene Im*
- 11 am MetALD Trials and Endpoints | *JP Arab*
- 11:20 am Panel Discussion / Q&A
- 11:40 am **BREAK & TABLETOP EXPO**
- 12:15 pm **LUNCH WITH INDUSTRY SYMPOSIUM**
SPONSORED BY MADRIGAL PHARMAUTICALS
Rezdiffra: Unlocking the Potential of a Liver-Directed Treatment | *Arun Jesudian, MD*

Session 3: Clinical Care Pathways in SLD –

Moderators: Meena Bansal and Jay Shubrook

- 1:15 pm Screening for SLD in Primary Care – Is This a Realistic Goal? | *Jay Shubrook*
- 1:35 pm Decentralizing the Role of PCP Using Digital Hepatology | *Alina Allen*
- 1:55 pm Including SLD Screening in USPSTF Recommendations – What Would It Take? | *Fasiha Kanwal*
- 2:15 pm Pros and Cons of Liver Health Screening in Diabetes as a Quality Measure | *Meena Bansal*
- 2:35 pm Panel Discussion / Q&A
- 2:55 pm **BREAK & TABLETOP EXPO**

Session 4: Patients' Perspectives and Public Health Approaches – Moderators: Grace Su and Elliott Tapper

- 3:30 pm Patients' Perspectives on the Harms and Benefits of Screening for SLD | *Jennifer Berg (Patient)*
- 3:50 pm How to Engage with the Congress and General Public to Increase Awareness of SLD | *AASLD Past President, Grace Su*
- 4:10 pm Public Health Measures and Screening Campaigns in SLD – What Can We Learn from Other Fields Such as Obesity or Cardiovascular Disease | *Scott Isaacs*
- 4:30 pm The Role of Social Media in Increasing Public Awareness in MASLD and ALD | *Elliott Tapper*
- 4:50 pm Panel Discussion / Q&A
- 5:10 pm **DAY 2 ADJOURNED**

SUNDAY, MARCH 15

Steatotic Liver Disease: From Bench to Clinical Care and Public Policy

Session 5: SLD Treatment and Prevention –

Moderators: Naim Alkhouri and Meena Bansal

- 8 am Review Trial Effectiveness of Currently Approved Medications for SLD and Obesity | *Rohit Loomba*
- 8:20 am Real-World Experience with Resmetirom and GLP-1 Agents After Approval | *Naim Alkhouri*
- 8:40 am Decreasing the Burden of SLD with Preventive Hepatology | *Pere Gines*
- 9 am Current Randomized Controlled Trials in SLD | *Mazen Noureddin*
- 9:20 am Panel Discussion / Q&A
- 9:40 am **BREAK & TABLETOP EXPO**

Session 6: Latest Findings in SLD Research (Oral Posters) –

Moderators: Alina Allen and Mazen Noureddin

- 10 am Keynote Lecture: How do we make an impactful change in SLD – from efficient diagnosis to effective care and public health interventions | *AASLD Past President, W. Ray Kim*
- 10:20-11:20 am Poster Presentations
- Weight-dependent and independent effects of semaglutide in participants with MASH: secondary analysis of the phase 3 ESSENCE trial | *Philip Newsome (tentative)*
- Improvements in non-invasive biomarkers and biopsy responses with the glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide: concordance analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fibrosis | *Quentin Anstee (tentative)*
- Validation of Agile-3+ and Agile-4 scores for Noninvasive Detection of Fibrosis and Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Latin America | *Carlos Esteban Coronel-Castillo (tentative)*
- A Randomized Controlled Trial in Silico for Risk Stratification in Population Screening for Fibrotic MASH | *Joseph Ahn (tentative)*
- 11:40 am Panel Discussion / Q&A
- NOON DAY 3 ADJOURNED**